Patients should have resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE, version 4.0, grade 1 or less
Patients should have resolution of any toxic effects of prior therapy (except fatigue and alopecia) to NCI CTCAE, version 4.0, grade 1 or less, including immune toxicity
Resolution of all toxic side effects from prior oncology treatments
All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to grade less than or equal to (<=) 1, except alopecia (any grade) and Grade 2 peripheral neuropathy
All acute toxic effects of any prior antitumor therapy resolved to Grade ?1 before baseline, with the exception of alopecia and neurotoxicity (CTCAE Grade 1 or 2 permitted).
Resolution of all acute toxic effects of prior therapy or surgical procedures to Grade ?1 (except alopecia).
Subjects must have resolution of toxic effect(s) from prior therapy to Grade 1 or less. Subjects with ? Grade 2 neuropathy or alopecia are an exception to this criterion. If a subject received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention to Grade 1 or less
All clinically significant toxic effects (except peripheral neuropathy) of prior locoregional therapy, surgery, or other anticancer therapy have resolved to =< CTCAE grade 1
Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy to grade 1 or less (except alopecia)
Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade <1 (except alopecia or neuropathy).
All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade less than or equal to (<=) 1, except alopecia (any grade) and Grade 2 peripheral neuropathy
All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to grade less than or equal to 1, except alopecia (any grade) and grade 2 peripheral neuropathy
All acute toxic effects of any prior antitumor therapy resolved to Grade 1.
Recovery from non-hematologic toxic effects of prior therapy to grade ? 1 (except alopecia) by NCI CTCAE Version 4.03;
(For both cohorts A and B): Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy to grade 1 or less (except alopecia)
Patients must have resolution of toxic effects to grade 1 or less from prior therapy (except alopecia)
All acute toxic effects of any prior radiotherapy, chemotherapy, experimental drug treatment or surgical procedure must have resolved to grade =< 1, except alopecia (any grade) and peripheral neuropathy
All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to grade =< 1, except alopecia (any grade) and < grade 2 peripheral neuropathy
Resolution of all acute toxic effects of prior therapy, including radiotherapy to grade ? 1 (except toxicities not considered a safety risk for the patient) and recovery from surgical procedures
CERITINIB INCLUSION CRITERIA: Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to CTCAE v4.03 grade =< 1
REGORAFENIB INCLUSION CRITERIA: Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to CTCAE v4.03 grade =< 1
ENTRECTINIB INCLUSION CRITERIA: Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy, chemotherapy or surgical procedures to CTCAE v4.03 grade =< 1
Subjects in the combination treatment cohort must not have: a history or evidence of psychiatric, substance abuse, or any other clinically significant disorder; toxic effects of the most recent prior chemotherapy not resolved to grade 1 or less (except alopecia); or expected other cancer therapy while on study with the exception of local radiation to the site of bone or other metastasis for palliative treatment.
Resolution of all acute toxic effects of previous anticancer therapy
Resolution of any toxic effects of prior therapy to Grade ?1 according to NCI CTCAE, version 4.0 (exception of alopecia and ? Grade 2 peripheral neuropathy).
Resolution of any toxic effects of previous therapies
All acute toxic effects of any prior antitumor therapy must be resolved to grade ? 1 before enrollment, with the exception of alopecia (any grade permitted), or bone marrow parameters (any grades permitted)
Resolution of all acute toxic effects of prior therapy or surgical procedure to grade 1 or baseline prior to randomization
Lack of recovery from toxic effects of previous treatment for RCC ? grade 1 with the exception of alopecia, unless stabilized under adequate medical control.
All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade less than or equal to 1 or returned to baseline except alopecia (any grade) and Grade 2 peripheral neuropathy
Resolution of all acute toxic effects of prior anti cancer therapy or surgical procedures to NCI CTCAE version 4.0 Grade ?1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).
All acute toxic effects of any prior antitumor therapy resolved to Grade ? 1 before the start of study drug
Participant must have resolution to Grade 1 or lower of any toxic effects (excepting alopecia) of the most recent therapy prior to Cycle 1 Day 2.
Resolution of all clinically relevant acute non-hematologic toxic effects of any prior antitumor therapy resolved to Grade <=1
Resolution of any toxic effects (excepting alopecia) of the most recent therapy
Resolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). Subjects with ? Grade 2 neuropathy are an exception and may enroll.
All acute toxic effects of any prior antitumor therapy resolved to Grade ? 1 before the start of study drug dosing (with the exception of alopecia [Grade 1 or 2 permitted] and neurotoxicity [Grade 1 or 2 permitted])
Resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (Parts 1A and 1B) and/or recovered from major surgery or radiation therapy
Adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures
Resolution of (non-laboratory) adverse effects of recent surgery, radiotherapy, or chemotherapy to grade =<1 prior to first study treatment (with the exception of alopecia or neuropathy; chemotherapy-induced peripheral neuropathy up to grade =< 2 will be permitted)
Resolution of all acute toxic effects of prior therapy or surgical procedure to Grade <= 1 or baseline prior to randomization
Resolution of all acute toxic effects of any prior treatments to NCI CTC (Version 3.0) grade <=1
Resolution of (non-laboratory) adverse effects of recent surgery, radiotherapy, or chemotherapy to grade =< 1 prior to first study treatment (with the exception of alopecia or neuropathy)
Resolution of all acute toxic effects of any prior treatments to NCI CTC (Version 3.0) grade <=1
Clinically significant toxic effects of any prior antitumor therapy (except hydroxyurea) resolved to Grade ? 1 before the start of study therapy (bone marrow parameters [Grade 1 to 4 permitted]);
Resolution to Grade ? 1 Adverse Events, of all clinically significant toxic effects of prior therapy
All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade </= 1, except alopecia (any grade) and Grade 2 peripheral neuropathy
Resolution of adverse effects of recent surgery, radiotherapy, or chemotherapy to grade =< 1 prior to first study treatment (with the exception of alopecia or neuropathy)
Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade ?1 (except alopecia or neuropathy)
Resolution of all acute toxic effects of prior chemotherapy, and other cancer treatments
Resolution of non-hematologic toxic effect(s) of NAC to =< grade 1 or baseline (except alopecia)
Persistent toxic effects with severity of CTCAE grade 2 or greater (excluding alopecia) caused by previous treatment
All acute toxic effects of any prior antitumor therapy resolved to Grade ? 1 before enrollment, with the exception of alopecia (any grade permitted)
Recovered (i.e., Grade ? 1 or to a baseline level) from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other therapies for cancer (with the exception of alopecia for which no resolution is required and peripheral neuropathy which must have resolved to Grade ? 1 for subjects receiving prior taxane-based chemotherapy);
Resolution of acute toxic effects of prior chemotherapy and other cancer treatments
Acute toxic effects of previous anticancer chemotherapy or immunotherapy have to be normalized to CTCAE Grade equal or lower than 1 (excluding alopecia)
Resolution of all acute toxicity effects of prior therapy to NCI CTCAE (version 4.0) grade =< 1, with the exception of unresolved grade 2 neuropathy and grade 2 alopecia, which are allowed
Resolution to Grade ? 1 Adverse Events, of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (except alopecia)
Resolution of all clinically significant toxic effects of prior therapy.
Patients who are currently part of any clinical investigation or who has not had resolution of all acute toxic effects or prior anti-cancer therapy to NCI CTCAE version 4.03 Grade 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).
All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade less than or equal to (<=) 1 or returned to baseline, except alopecia (any grade) and Grade 2 peripheral neuropathy
Resolution of all toxic effects of prior treatments (except alopecia) to Grade <=1 NCI CTCAE, Version 4.03.
